Searchable abstracts of presentations at key conferences in endocrinology

ea0016p235 | Diabetes and cardiovascular diseases | ECE2008

Cumulative incidence, timing and risk factors for thyroid dysfunction in 144 Romanian patients treated with amiodarone

Trifanescu Raluca-Alexandra , Fica Simona , Ion Oana-Gabriela , Coculescu Mihail

Aim: To assess cumulative incidence and risk factors for amiodarone-induced thyroid dysfunction (AITD) in a large cohort of Romanian subjects.Subjects and methods: One hundred and forty-four patients (59 M/85 F), mean age 61.4±0.9 years, treated 2.4±0.2 years with amiodarone were assessed for TSH, TT3, TT4 (immunoradiometric assays) and FT4, TPO Ab (microenzymatic immunoassays). Thirty-three patients were reside...

ea0056p84 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2018

Metabolic and hormonal profile in primary aldosteronism as compared with essential hypertension

Trifanescu Raluca , Smarandoiu Alexandra , Caragheorgheopol Andra , Iordachescu Carmen , Poiana Catalina

Background: Primary aldosteronism is associated with increased vascular mortality and morbidity.Aims: We aimed to assess metabolic and hormonal profile differences in patients with primary aldosteronism (PA) compared with patients with essential hypertension (EH).Patients and methods: Thirty-one patients (11 M/20 F) with primary aldosteronism, aged 46.2±12.9 years and 64 patients (24 M/40 F) with essential hypertension, aged 4...

ea0073aep541 | Pituitary and Neuroendocrinology | ECE2021

Successful recovery after COVID-19 infection in a patient with diabetes insipidus and pituitary insufficiency due to a pituitary stalk tumor

Trifanescu Raluca , Schipor Sorina , Vladoiu Suzana , Poiana Catalina

BackgroundFluid balance in patients with diabetes insipidus and COVID-19 is very fragile. The prevalence of hyponatraemia in patients with pneumonia due to COVID-19 seems to be low, but in patients admitted to intensive care units (ICU) is high (up to 20.5%). In contrast, hypernatraemia may also develop in COVID-19 patients in ICU (up to 3.7% of cases), due to insensible water losses from pyrexia, increased respiration rate and use of diuretics. Both hyp...

ea0099p244 | Adrenal and Cardiovascular Endocrinology | ECE2024

Cardiovascular risk in patients with primary hyperparathyroidism

Trifanescu Raluca , Mohora Maria , Toma Iustin , Nitu Ileana , Poiana Catalina

Background: PTH is a hormone with vascular and cardiovascular properties, involved in the expression of endothelial pro-atherosclerotic and pro-inflammatory parameters. Both hypercalcemic and normocalcemic primary hyperparathyroidism (PHPT) were associated with increased cardiovascular risk.Patients and methods: 84 patients (6M/78F) with PHPT, aged 58.9±12.7 years, were retrospectively reviewed. Serum calcium levels, PTH and 25 OH vitamin D levels w...

ea0081ep33 | Adrenal and Cardiovascular Endocrinology | ECE2022

Large adrenal tumor in paucisymptomatic ACTH – independent Cushing syndrome’s patient – a clinical case

Mohora Maria-Alexandra , Trifanescu Raluca , Andra Caragheorgheopol , Carmen Iordachescu , Dan Hortopan , Poiana Catalina

Background: Cushing’s syndrome is represented by the cummulation of signs and symptoms of excess glucocorticoids and has many potential causes. Approximately 20 percent of all cases are represented by ACTH-independent adrenal tumors – with a majority of these being represented by cortisol secreting adrenal adenomas. Generally, a large adrenal tumor has over 5 cm in diameter and the risk of it being malignant raises proportionately with the dimensions. Large adrenal t...

ea0050p297 | Neuroendocrinology and Pituitary | SFEBES2017

Recurrence rate of hyperprolactinemia after dopamine agonists withdrawal in macroprolactinoma patients

Trifanescu Raluca , Baranga Iuliana , Caragheorgheopol Andra , Dumitrascu Anda , Gheorghiu Monica , Poiana Catalina

Background: Dopamine agonists (DA) have excellent result in controlling both hyperprolactinemia and tumor volume in macroprolactinomas. However, even after long term DA treatment, withdrawal of dopamine agonists results in recurrence of hyperprolactinemia in a significant proportion of patients.Aim: To assess recurrence rate of hyperprolactinemia after DA withdrawal in a large series of patients treated in a tertiar...

ea0050p297 | Neuroendocrinology and Pituitary | SFEBES2017

Recurrence rate of hyperprolactinemia after dopamine agonists withdrawal in macroprolactinoma patients

Trifanescu Raluca , Baranga Iuliana , Caragheorgheopol Andra , Dumitrascu Anda , Gheorghiu Monica , Poiana Catalina

Background: Dopamine agonists (DA) have excellent result in controlling both hyperprolactinemia and tumor volume in macroprolactinomas. However, even after long term DA treatment, withdrawal of dopamine agonists results in recurrence of hyperprolactinemia in a significant proportion of patients.Aim: To assess recurrence rate of hyperprolactinemia after DA withdrawal in a large series of patients treated in a tertiar...

ea0090p554 | Adrenal and Cardiovascular Endocrinology | ECE2023

Unexpected cause of hypertension associated with hypokalemia

Trifanescu Raluca , Toma Iustin-Daniel , Mohora Maria-Alexandra , Popescu Ileana , Nitu Ileana , Poiana Catalina

Background: Prolonged ingestion of licorice has been known to cause hypokalemia and resistant hypertension amongst other disturbances. This is due to glycyrrhizin that inhibits the 11-β-hydroxysteroid dehydrogenase enzyme type 2 which results into increased plasma cortisol levels that stimulate the mineralocorticoid receptors resulting into apparent mineralocorticoid excess.Case report: A 45-year-old woman resident in an iodine sufficient area, heav...

ea0090p233 | Thyroid | ECE2023

Impact of SARS-COV-2 infection on the endocrine system: a case series

Cristiana Calin , Florentina Burcea Iulia , Dobre Ramona , Dumitriu Roxana , Trifanescu Raluca , Poiana Catalina

Introduction: There is evidence that SARS-COV-2 infection can result in development of endocrine disturbances. Expression of the angiotensin-converting enzyme 2, which is postulated to be at the center of the pathogenesis of COVID-19, has been reported in various endocrine tissues.Case Series: We retrospectively analyzed 12 patients with recent history of SARS-COV-2 infection: 5 cases with subacute thyroiditis (SAT), 2 cases with Graves’ disease, 2 ...

ea0065p288 | Neuroendocrinology | SFEBES2019

Modalities to overcome resistance to dopamine agonists in patients with macroprolactinomas

Trifanescu Raluca , Smarandoiu Alexandra , Baciu Ionela , Caragheorgheopol Andra , Dumitrascu Anda , Poiana Catalina

Background: Dopamine agonists (DA) are the first-line treatment for macroprolactinomas. However, up to 10% of patients fail to respond to medical therapy.Aim: To assess biochemical resistance rate to DA treatment in a large series of patients with macroprolactinoma and to analyze possibilities to overcome this resistance.Patients and methods: 195 patients with macroprolactinomas, treated with DA for at least 2 years, were retrospec...